Skip to main content
OpenTrials
Completed

NCT Number: NCT00900822

Straumann Bone Ceramic Versus BioOss in Sinus Elevation

Straumann Bone Ceramic (SBC) and BioOss will be used as bone grafting materials when there is a need for bone augmentation in the posterior upper jaw. 9 months later the bone formation is evaluated. The patients are followed for 3 years.The study hypothesis is that the SBC is not worse than BioOss.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Dr Mats Hallman

Gävle, 80187, Sweden

About this study

Straumann Bone Ceramic (SBC) and BioOss will be used as bone grafting materials when there is a need for bone augmentation in the posterior upper jaw. The bone grafting materials will be placed into the sinus cavity,(a routine procedure), one material randomly at each side and a micro-implant will be inserted simultaneously. 9 months later the micro-implant is removed and a regular Straumann SLActive implant is inserted. The micro-implant is evaluated histologically. The site is evaluated every 12 months for 3 years in regards to clinical measurements. The study hypothesis is that the SBC is not worse than BioOss.

Study design: Prospective, randomized, open, controlled, single center, split mouth

Study population: 11 male and female patients at an age of between 18 and 80 years, affected by edentulism of both lateral-posterior maxilla and presenting two pneumatized maxillary sinuses and necessitating rehabilitation with implant-supported prostheses will be recruited in the study and treated by means of maxillary sinus floor augmentation and delayed implant placement.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and females, 18 years to 80 years of age
  • The patients are at least partly edentulous in the both maxillary regions corresponding to the sinuses.
  • A dental implant procedure is foreseen in both maxilla regions corresponding to maxillary sinuses.
  • Patients must be expected to present a bilateral bone defect in the sinus area, which both need a sinus floor augmentation to place one or more dental implants each.
  • Residual alveolar crest height of the lateral-posterior segments of the edentulous maxilla below the floor of each of the maxillary sinuses shall be
  • less than 5 mm and at least 2 mm, as measured by Scanora - tomography Scans in the deepest floor of the sinus
  • residual alveolar crest width should be at least in average more than 4mm as measured by Scanora - tomography scans
  • Patients must be committed to the study and must sign informed consent.
  • Oral hygiene Index less than 25%

Exclusion criteria

  • Any systemic medical condition that could interfere with the surgical procedure or planned treatment
  • Current pregnancy at the time of recruitment
  • Physical handicaps that would interfere with the ability to perform adequate oral hygiene
  • Alcoholism or chronically drug abuse causing systemic compromize
  • Patients who smoke more than 10 cigarettes per day
  • Medication which interferes with bone formation
  • Conditions or circumstances, in the opinion of the investigator, which could represent a general contra-indication for surgical procedure or would prevent completion of study participation or interfere with analysis of study results, such as history of non-compliance, or unreliability
  • Mucosal diseases such as erosive lichen planus
  • History of local radiation therapy
  • Presence of oral lesions (such as ulceration, malignancy)
  • Severe bruxing or clenching habits
  • Persistent intraoral infection
  • Previous GBR (bone graft) or dental implant treatment in the posterior segments of the upper maxilla (foreseen implant site)
  • Patients presenting clinical and radiological signs and symptoms of maxillary sinus disease
  • Existing teeth in the residual dentition with untreated endodontic problems

Treatment and study plan

Straumann Bone Ceramic

Device

Granules applied once during surgery

BioOss

Device

Granules that are applied once during surgery

Primary outcomes

  1. Histologically Measured Bone to Implant Contact (BIC)

    Time frame: 9 months after implant placement

    Results from morphometric measurements of percentage of new bone in contact with the total surface of the titanium implant, area of new bone and bone graft particles in contact with bone

Secondary outcomes

  1. Implant Survival Rate

    Time frame: 12 months after loading the implant

    The percentage of implants remaining in the jaw.

  2. Implant Success Rate

    Time frame: 12 months after loading the implant

    Implant success is defined as the absence of any continuous peri-implant radiolucency based on radiographic findings, absence of implant mobility, absence of a recurrent per-implant infection with suppuration (where an infection is termed recurrent if it is observed at two or more 3-month follow-up visits after treatment with systemic antibiotics), and bone level changes around the implant less than 1 mm during the first year of loading and less than 0.2 mm per year thereafter.

Sponsors and collaborators

Lead sponsor

Institut Straumann AG

Industry

Registry information

Official study title

Randomized, Controlled Clinical Study to Compare Bone Formation Around Micro-implants in the Maxilla After Sinus Floor Augmentation With Straumann Bone Ceramic or Bio-Oss in a Split Mouth Design

Important dates

Study start
2005
Primary completion
2007
Study completion
2008
First posted
May 13, 2009
Registry last updated
Mar 31, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.